Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Randomised controlled trial of cognitive behavioural treatment of obsessional compulsive disorder in children and adolescents.
ISRCTN ISRCTN54248464
ClinicalTrials.gov identifier
Public title Randomised controlled trial of cognitive behavioural treatment of obsessional compulsive disorder in children and adolescents.
Scientific title
Acronym N/A
Serial number at source SPGS 808
Study hypothesis To evaluate the efficacy of cognitive behavioural treatment for children and adolescents with obsessive compulsive disorder. OCD is a severely handicapping chronic relapsing psychological disorder with affects 0.5% to 2% of the population. 50% of adults with OCD develop the condition in adolescence, and 50% of the children with OCD continue to be disabled by it in adulthood. Although cognitive behavioural treatment (CBT) is the first choice treatment in childhood according to recent consensus guidelines, there has only been one RCT in adolescents and children. That study suffers from difficulties of interpretation and used a less powerful form of CBT than the best currently used with adults. RCTs in adulthood have found that 70& of patients with OCD benefit from CBT, and remain well following the end of treatment.
Research Objectives: To carry out a trial of a manulised cognitive behavioural treatment for obsessional compulsive disorder in children and adolescents, in order to ensure that it is effective in reducing the level of symptoms. To investigate the extent of the improvements in functioning resulting from the treatment method and compare them with the effects of time spent waiting for treatment.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Obsessive compulsive disorder (OCD)
Participants - inclusion criteria Children and adolescents aged between 8 years and 18 years of age in full time education with obsessional compulsive disorder defined by research diagnostic criteria and whose medication has remained stable for 12 weeks prior to entry to trial.
Participants - exclusion criteria Children with severe learning disabilities or severe language difficulties - because the treatment requires the use of verbal reasoning skills at the eight year plus level
Anticipated start date 01/10/1999
Anticipated end date 30/03/2002
Status of trial Completed
Patient information material
Target number of participants 21 (added 08/01/10, see publication)
Interventions 1. Cognitive behavioural treatment
2. Waitlist control
Primary outcome measure(s) The clinical status of the children and adolescents will be the main focus of the trial. The following tools will be used:
1. KIDDIE-SADS or equivalent semi-structured interview used to assess Mental state of the children
2. YBOCS (child version) used to measure obsessional compulsive symptoms by interview
3. Obsessive compulsive Inventory (OCI) - self-report measure of OCD
4. Responsibility Interpretation Questionnaire (RIQ) - self-report to measure cognitions specific to the treatment methods
5. Children's Depression Inventory (CDI)
6. Multidimensional Anxiety Scale for children (MASC) - self report
7. National Institute of Mental Health (NIMH) global obsessive compulsive scale

Following the example of most other studies in this field the YBOCS total score is considered to be the main focus of analysis.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding NHS Executive South East (UK)
Trial website
Publications 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19921305
Contact name Dr  Tim  Williams
  Address 3 Craven Road
  City/town Reading
  Zip/Postcode RG1 5LF
  Country United Kingdom
  Tel +44 (0)118 9315800
  Fax +44 (0)118 9750297
  Email sxswiams@reading.ac.uk
Sponsor NHS R&D Regional Programme Register - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Fax +44 (0)20 7307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.doh.gov.uk
Date applied 23/01/2004
Last edited 08/01/2010
Date ISRCTN assigned 23/01/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central